See more : Baird Medical Investment Holdings Limited (BDMD) Income Statement Analysis – Financial Results
Complete financial analysis of Chongqing Pharscin Pharmaceutical Co., Ltd. (002907.SZ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Chongqing Pharscin Pharmaceutical Co., Ltd., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Vincit Oyj (VINCIT.HE) Income Statement Analysis – Financial Results
- Kawasaki Kisen Kaisha, Ltd. (KAKKF) Income Statement Analysis – Financial Results
- Tractor Supply Company (TSCO) Income Statement Analysis – Financial Results
- Formosa Taffeta Co., Ltd. (1434.TW) Income Statement Analysis – Financial Results
- Lionheart Holdings Unit (CUBWU) Income Statement Analysis – Financial Results
Chongqing Pharscin Pharmaceutical Co., Ltd. (002907.SZ)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.pharscin.com
About Chongqing Pharscin Pharmaceutical Co., Ltd.
Chongqing Pharscin Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of drugs in China. The company offers tablets, powders, granules, hard capsules, soft capsules, powder injections, freeze-dried powder injections, small volume injections, and API synthesis. It provides its products in the areas of CNS, digestion, otolaryngology, oncology, cardiovascular, and cerebrovascular related diseases. Chongqing Pharscin Pharmaceutical Co., Ltd. was founded in 1996 and is headquartered in Chongqing, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 691.54M | 785.18M | 846.14M | 882.47M | 842.06M | 703.42M | 592.10M | 551.67M | 469.32M | 425.90M | 347.37M |
| Cost of Revenue | 311.35M | 319.29M | 399.93M | 458.31M | 307.08M | 230.77M | 195.36M | 196.57M | 178.11M | 154.39M | 128.59M |
| Gross Profit | 380.19M | 465.89M | 446.22M | 424.17M | 534.98M | 472.65M | 396.73M | 355.09M | 291.21M | 271.52M | 218.78M |
| Gross Profit Ratio | 54.98% | 59.34% | 52.74% | 48.07% | 63.53% | 67.19% | 67.01% | 64.37% | 62.05% | 63.75% | 62.98% |
| Research & Development | 70.84M | 58.82M | 41.72M | 36.48M | 25.56M | 15.22M | 8.70M | 4.06M | 7.01M | 8.61M | 0.00 |
| General & Administrative | 9.91M | 8.14M | 5.12M | 12.50M | 10.81M | 7.57M | 9.75M | 5.89M | 3.86M | 2.67M | 22.21M |
| Selling & Marketing | 210.74M | 245.93M | 258.59M | 225.15M | 290.79M | 279.34M | 239.26M | 218.08M | 179.04M | 181.35M | 159.78M |
| SG&A | 262.28M | 254.08M | 263.71M | 237.64M | 301.60M | 286.91M | 249.01M | 223.97M | 182.90M | 184.03M | 182.00M |
| Other Expenses | 519.01K | 34.00M | 34.17M | 11.52M | 6.71M | 2.44M | 1.33M | 21.54M | 17.29M | 13.08M | 10.00M |
| Operating Expenses | 334.37M | 346.90M | 339.60M | 285.65M | 333.86M | 314.35M | 265.64M | 256.70M | 213.29M | 209.24M | 185.86M |
| Cost & Expenses | 645.72M | 666.19M | 739.52M | 743.95M | 640.95M | 545.12M | 461.01M | 453.27M | 391.40M | 363.63M | 314.45M |
| Interest Income | 9.81M | 11.50M | 16.40M | 10.37M | 3.30M | 2.16M | 386.59K | 828.25K | 1.78M | 1.35M | -0.82 |
| Interest Expense | 1.01M | 14.42M | 18.22M | 17.21M | 9.20M | 1.25M | 1.06M | 2.52M | 5.75M | 5.21M | 4.45M |
| Depreciation & Amortization | 82.11M | 72.65M | 67.33M | 47.32M | 23.74M | 20.79M | 20.43M | 19.74M | 16.69M | 13.99M | 6.21M |
| EBITDA | 125.85M | 200.49M | 192.96M | 202.22M | 230.95M | 182.97M | 153.88M | 135.73M | 109.61M | 89.38M | 33.80M |
| EBITDA Ratio | 18.20% | 25.53% | 22.53% | 22.62% | 27.18% | 26.67% | 26.18% | 25.08% | 23.36% | 21.29% | 9.73% |
| Operating Income | 45.82M | 108.83M | 103.31M | 137.44M | 198.26M | 158.47M | 131.05M | 93.63M | 73.48M | 56.70M | 27.59M |
| Operating Income Ratio | 6.63% | 13.86% | 12.21% | 15.57% | 23.54% | 22.53% | 22.13% | 16.97% | 15.66% | 13.31% | 7.94% |
| Total Other Income/Expenses | -3.03M | -589.15K | 107.80K | -389.06K | -269.77K | 2.44M | 1.33M | 19.82M | 13.28M | 13.08M | 9.99M |
| Income Before Tax | 42.80M | 108.24M | 103.42M | 137.05M | 197.99M | 160.91M | 132.38M | 113.45M | 86.76M | 69.79M | 37.57M |
| Income Before Tax Ratio | 6.19% | 13.79% | 12.22% | 15.53% | 23.51% | 22.88% | 22.36% | 20.57% | 18.49% | 16.39% | 10.82% |
| Income Tax Expense | 10.10M | 9.84M | 11.64M | 17.86M | 28.25M | 23.54M | 20.39M | 17.74M | 14.07M | 10.48M | 8.54M |
| Net Income | 32.70M | 98.40M | 91.78M | 119.19M | 169.75M | 137.37M | 111.99M | 95.71M | 73.84M | 58.75M | 28.95M |
| Net Income Ratio | 4.73% | 12.53% | 10.85% | 13.51% | 20.16% | 19.53% | 18.91% | 17.35% | 15.73% | 13.80% | 8.33% |
| EPS | 0.08 | 0.24 | 0.23 | 0.30 | 0.42 | 0.34 | 0.31 | 0.27 | 0.21 | 0.73 | 0.08 |
| EPS Diluted | 0.08 | 0.24 | 0.23 | 0.30 | 0.42 | 0.34 | 0.31 | 0.27 | 0.21 | 0.73 | 0.08 |
| Weighted Avg Shares Out | 417.61M | 403.12M | 400.50M | 400.51M | 400.06M | 400.03M | 366.69M | 359.94M | 360.00M | 360.00M | 360.00M |
| Weighted Avg Shares Out (Dil) | 417.61M | 403.12M | 401.14M | 400.90M | 400.06M | 400.03M | 366.69M | 359.94M | 360.00M | 360.00M | 360.00M |
Source: https://incomestatements.info
Category: Stock Reports